PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer

Shimomura,Masahiro; Fukuda,Takeshi; Awazu,Yuichiro; Nanno,Shigenori; Inoue,Yuta; Matsubara,Hiroaki; Yamauchi,Makoto; Yasui,Tomoyo; Sumi,Toshiyuki

doi:10.3892/ol.2020.12411

PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer

Authors:
- Masahiro Shimomura
- Takeshi Fukuda
- Yuichiro Awazu
- Shigenori Nanno
- Yuta Inoue
- Hiroaki Matsubara
- Makoto Yamauchi
- Tomoyo Yasui
- Toshiyuki Sumi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: December 24, 2020 https://doi.org/10.3892/ol.2020.12411
Article Number: 150
Copyright: © Shimomura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The standard care for patients with locally advanced cervical cancer is concurrent chemoradiotherapy. Successful neoadjuvant chemotherapy (NAC) can reduce tumor size and enable patients to be eligible for a hysterectomy, which can improve their prognosis. Selecting the right candidate for NAC is important since NAC failure results in switching to radiation therapy and can lead to a worse prognosis due to a delay in the initiation of the core therapy. Therefore, the identification of biomarkers that can predict the effect of NAC is essential. Previous reports have suggested a relationship between protein arginine methyltransferase (PRMT1) and chemoresistance in several types of cancer. PRMT1 has been demonstrated to methylate apoptosis signal‑regulated kinase 1 and to inhibit its activity, thereby contributing to chemoresistance. The present study investigated the association between PRMT1 expression and the efficacy of NAC in locally advanced cervical cancer. Data from 53 patients with locally advanced uterine cervical cancer who were classified into two groups based on effective (n=28) and ineffective (n=25) responses to NAC treatment were evaluated. PRMT1 expression was investigated by immunohistochemistry and scored using a weighted scoring system. Additionally, the present study investigated the effect of RNA interference‑mediated downregulation of PRMT1 on the sensitivity of cervical cancer cells to cisplatin in vitro. The results demonstrated that the NAC effective group had significantly lower weighted PRMT1 scores than the NAC ineffective group (P=0.030). In addition, lower tumor expression levels of PRMT1 were significantly associated with increased sensitivity to NAC (P=0.033). Furthermore, downregulation of PRMT1 expression in cervical cancer cells markedly improved their sensitivity to cisplatin in vitro. The present study suggested that PRMT1 expression has potential as a predictive marker of the efficacy of NAC in patients with locally advanced cervical cancer. This finding can contribute to improvements in the prognosis of these patients.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2011. View Article : Google Scholar
2	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
3	Japan Society of Gynecologic Oncology (eds), . Formulation Committee of the Treatment Guidelines for Cervical Cancer, 2011. Kanehara & Co.; Tokyo: 2011, (In Japanese).
4	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer Version II. 2013.simplehttps://www2.tri-kobe.org/nccn/guideline/gynecological/english/cervical.pdf
5	Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
6	Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ishiko O, Sumi T, Yasui T, Matsumoto Y, Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R: Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix. Oncol Rep. 7:141–144. 2000.PubMed/NCBI
8	Souhami L, Gil RA, Allan SE, Canary PC, Araújo CM, Pinto LH and Silveira TR: A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991. View Article : Google Scholar : PubMed/NCBI
9	Tattersall MH, Lorvidhaya V, Vootiprux V, Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen MS, et al: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical cancer study group of the asian oceanian clinical oncology association. J Clin Oncol. 13:444–451. 1995. View Article : Google Scholar : PubMed/NCBI
10	Ishiko O, Sumi T, Yasui T, Matsumoto Y, Ogita S, Kaminou T, Nakamura K and Yamada R: Tumor marker and MR imaging criteria for evaluating the efficacy of cyclic balloon-occluded arterial infusion for advanced cancer of the uterine cervix. Oncol Rep. 7:827–830. 2000.PubMed/NCBI
11	Ishiko O, Sumi T, Yoshida H, Ogita S and Yamada R: Expression of apoptosis regulatory proteins in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion chemotherapy. Int J Oncol. 18:1151–1155. 2001.PubMed/NCBI
12	Okamoto E, Sumi T, Misugi F, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O: Expression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapy. Int J Mol Med. 15:41–47. 2005.PubMed/NCBI
13	Nobeyama H, Sumi T, Misugi F, Okamoto E, Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O: Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. Int J Mol Med. 14:101–105. 2004.PubMed/NCBI
14	Benedetti Panici P, Bellati F, Manci N, Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and Angioli R: Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer. Ann Surg Oncol. 14:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
15	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
16	Wang Q, Shi S, He W, Padilla MT, Zhang L, Wang X, Zhang B and Lin Y: Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget. 5:1304–1314. 2014. View Article : Google Scholar : PubMed/NCBI
17	Bedford MT and Richard S: Arginine methylation an emerging regulator of protein function. Mol Cell. 18:263–72. 2005. View Article : Google Scholar : PubMed/NCBI
18	Baldwin RM, Morettin A and Côté J: Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World J Biol Chem. 5:115–129. 2014.PubMed/NCBI
19	Hirata Y, Katagiri K, Nagaoka K, Morishita T, Kudoh Y, Hatta T, Naguro I, Kano K, Udagawa T, Natsume T, et al: TRIM48 promotes ASK1 activation and cell death through ubiquitination-dependent degradation of the ASK1-negative regulator PRMT1. Cell Rep. 21:2447–2457. 2017. View Article : Google Scholar : PubMed/NCBI
20	Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, et al: PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 125:4529–4543. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhao Y, Lu Q, Li C, Wang X, Jiang L, Huang L, Wang C and Chen H: PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation. Cell Death Dis. 10:3592019. View Article : Google Scholar : PubMed/NCBI
22	Tsuji K, Yamada R, Kawabata M, Mitsuzane K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon occluded arterial infusion of anticancer drugs on the prognosis of cervical cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
23	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Cho JH, Lee MK, Yoon KW, Lee J, Cho SG and Choi EJ: Arginine methylation-dependent regulation of ASK1 signaling by PRMT1. Cell Death Differ. 19:859–870. 2012. View Article : Google Scholar : PubMed/NCBI